Thyroid Dysfunction Following Sunitinib
One of the risks associated with the chemotherapy drug sunitinib (SUTENT®) is thyroid dysfunction. Sunitinib can cause an underactive or overactive thyroid during treatment. In most cases, this dysfunction that occurs with sunitinib is reversible following treatment. To help ensure your safety, your healthcare provider will monitor your thyroid function with a blood test before you start the medication and observe you closely for problems while you are taking it.
(For more information, click Warnings and Precautions With Sunitinib. This article gives a more in-depth description of the safety warnings associated with this drug, including information on what to discuss with your healthcare provider and who should avoid it altogether.)